13:56 14/09/2016 Stock Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Announces Expiration ...
Stock Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Announces Expiration ...
Smarter Analyst - Sep 14, 2016
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that the remaining 8,064 Series B Common Share Purchase Warrants (the “Series B Warrants”) issued in connection with the Company's March 2015 financing expired on September 12, 2016 without ...

22:11 22/08/2016 Canaccord Positive on AEterna Zentaris Inc. (USA) (AEZS) Following 2Q:16 Update
Canaccord Positive on AEterna Zentaris Inc. (USA) (AEZS) Following 2Q:16 Update
Smarter Analyst - Aug 22, 2016
On August 9th, AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) posted second-quarter results and provided a clinical update.

15:26 11/08/2016 Maxim Analyst Shares Two Cents on AEterna Zentaris Inc. (USA) (AEZS) Amid 2Q ...
Maxim Analyst Shares Two Cents on AEterna Zentaris Inc. (USA) (AEZS) Amid 2Q ...
Smarter Analyst - Aug 11, 2016
Maxim analyst Jason Kolbert offers commentary on shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) after the biotech firm reported its second-quarter results and provided a corporate update on its clinical progress.

21:44 09/08/2016 Company Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Reports Second ...
Company Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Reports Second ...
Smarter Analyst - Aug 9, 2016
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today reported financial and operating results for the ...

14:41 08/08/2016 Stock Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Expands Promotion of ...
Stock Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Expands Promotion of ...
Smarter Analyst - Aug 8, 2016
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that it is expanding its promotion of APIFINY®, the only cancer-specific, non-PSA blood test available to assess the risk for the presence of prostate cancer, into the important Florida market ...

19:51 01/08/2016 Maxim Analyst Sees Exceptional Value in AEterna Zentaris Inc. (USA) (AEZS ...
Maxim Analyst Sees Exceptional Value in AEterna Zentaris Inc. (USA) (AEZS ...
Smarter Analyst - Aug 1, 2016
Maxim analyst Jason Kolbert remains bullish on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) after the oncology drug maker just made waves signing a licensed agreement deal for Zoprtex, a new peptide-conjugated chemical entity designed to treat ...

18:55 11/07/2016 HC Wainwright Analyst Pounds the Table on AEterna Zentaris Inc. (USA)
HC Wainwright Analyst Pounds the Table on AEterna Zentaris Inc. (USA)
Smarter Analyst - Jul 11, 2016
H.C. Wainwright analyst Swayampakula Ramakanth was out pounding the table on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) Monday, reiterating a Buy rating and price target of $12, which represents a potential upside of 258% from where the stock is ...

16:09 05/07/2016 Analysts Shine Light On AEterna Zentaris Inc. (USA) (AEZS) And OraSure ...
Analysts Shine Light On AEterna Zentaris Inc. (USA) (AEZS) And OraSure ...
Smarter Analyst - Jul 5, 2016
Healthcare analysts explain their bullish views on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) and OraSure Technologies, Inc. (NASDAQ:OSUR) following the signing and termination of agreements, respectively.

18:21 15/06/2016 Maxim Reiterates Buy on AEterna Zentaris Inc. (USA) (AEZS) Following IND ...
Maxim Reiterates Buy on AEterna Zentaris Inc. (USA) (AEZS) Following IND ...
Smarter Analyst - Jun 15, 2016
In a research report issued Wednesday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), with a price target of $11, after the company announced that its licensee Sinopharm A-Think ...

22:25 06/06/2016 Company Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Reconfirms ...
Company Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Reconfirms ...
Smarter Analyst - Jun 6, 2016
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) reconfirmed its commitment to LHRH-receptor targeted therapy and its expectation that the pivotal, phase 3 trial for Zoptrex™ (zoptarelin doxorubicin) in women with advanced, recurrent endometrial cancer, ...
AEterna Zentaris Reconfirms Commitment to Zoptrex; Phase III Trial for ... - Sonoran Weekly Review